0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Piperacillin To Prevent Cholangitis after Endoscopic Retrograde Cholangiopancreatography: A Randomized, Controlled Trial

Sven J. van den Hazel, MD, PhD; Peter Speelman, MD, PhD; Jacob Dankert, MD, PhD; Kees Huibregtse, MD, PhD; Guido N.J. Tytgat, MD, PhD; and Dirk J. van Leeuwen, MD, PhD
[+] Article and Author Information

From the Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands; and the University of Alabama at Birmingham, Birmingham, Alabama. Grant Support: In part by Cyanamid/Lederle (Etten-Leur, the Netherlands), the manufacturer of piperacillin. Requests for Reprints: Sven J. van den Hazel, MD, PhD, Department of Gastroenterology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. Current Author Addresses: Drs. van den Hazel, Huibregtse, and Tytgat: Department of Gastroenterology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. Dr. Speelman: Department of Internal Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;125(6):442-447. doi:10.7326/0003-4819-125-6-199609150-00002
Text Size: A A A

Background: Cholangitis does not often occur after endoscopic retrograde cholangiopancreatography (ERCP), but it can be a serious complication of this procedure. Antibiotic prophylaxis is therefore frequently used in patients having ERCP, but existing data are insufficient to allow evaluation of the effectiveness of this practice.

Objective: To determine the efficacy of single-dose antibiotic prophylaxis with piperacillin for ERCP-induced cholangitis.

Design: Randomized, double-blind, placebo-controlled clinical trial.

Setting: Tertiary referral center for ERCP.

Patients: Patients who had ERCP for suspected biliary tract stones or distal common bile duct stricture were eligible. Major exclusion criteria were previous ERCP within 7 days, biliary endoprosthesis in situ, and use of antimicrobial agents or presence of fever within 7 days before the procedure.

Intervention: Piperacillin, 4 g, or placebo was given intravenously approximately 30 minutes before ERCP.

Measurements: Duration of follow-up was 1 week. Acute cholangitis was diagnosed if a patient had a body temperature greater than 38 °C, a clinically apparent need for antibiotic treatment, and no symptoms indicating infection outside of the biliary tree.

Results: 551 consecutive patients were enrolled. During ERCP, stones were found in 147 patients, malignant distal strictures were found in 203 patients, other pathologic findings were seen in 88 patients, and normal biliary tracts were seen in 113 patients. Seventeen of the 281 patients who received placebo (6.0%) and 12 of the 270 patients who received piperacillin (4.4%) developed acute cholangitis (relative risk, 0.73 [95% CI, 0.36 to 1.51]). The absolute risk reduction was 1.6% (CI, −5.3% to 2.1%). All cases of cholangitis (with the exception of one case seen in a patient in the piperacillin group) were mild or moderate in severity.

Conclusion: Single-dose prophylaxis with piperacillin is not associated with a clinically significant reduction in the incidence of acute cholangitis after ERCP in patients suspected of having biliary tract stones or distal common bile duct stricture.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)